NASDAQ:DWTX - Nasdaq - US92829J2033 - Common Stock - Currency: USD
NASDAQ:DWTX (7/23/2025, 4:12:44 PM)
4.82
+0.13 (+2.77%)
The current stock price of DWTX is 4.82 USD. In the past month the price decreased by -1.47%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.55 | 336.59B | ||
AMGN | AMGEN INC | 14.89 | 166.27B | ||
GILD | GILEAD SCIENCES INC | 14.67 | 141.26B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 122.48B | ||
REGN | REGENERON PHARMACEUTICALS | 12.92 | 61.80B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 42.46B | ||
ARGX | ARGENX SE - ADR | 100.07 | 35.13B | ||
ONC | BEONE MEDICINES LTD-ADR | 7.54 | 31.91B | ||
BNTX | BIONTECH SE-ADR | N/A | 27.55B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.80B | ||
INSM | INSMED INC | N/A | 19.62B | ||
BIIB | BIOGEN INC | 8.28 | 19.19B |
Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. The company is headquartered in Alpharetta, Georgia and currently employs 12 full-time employees. The company went IPO on 2020-12-17. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).
DOGWOOD THERAPEUTICS INC
44 Milton Avenue
Alpharetta GEORGIA US
Employees: 12
Phone: 18666208655
The current stock price of DWTX is 4.82 USD. The price increased by 2.77% in the last trading session.
The exchange symbol of DOGWOOD THERAPEUTICS INC is DWTX and it is listed on the Nasdaq exchange.
DWTX stock is listed on the Nasdaq exchange.
8 analysts have analysed DWTX and the average price target is 17.34 USD. This implies a price increase of 259.75% is expected in the next year compared to the current price of 4.82. Check the DOGWOOD THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
DOGWOOD THERAPEUTICS INC (DWTX) has a market capitalization of 9.21M USD. This makes DWTX a Nano Cap stock.
DOGWOOD THERAPEUTICS INC (DWTX) currently has 12 employees.
DOGWOOD THERAPEUTICS INC (DWTX) has a support level at 4.6 and a resistance level at 4.8. Check the full technical report for a detailed analysis of DWTX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
DWTX does not pay a dividend.
DOGWOOD THERAPEUTICS INC (DWTX) will report earnings on 2025-08-06.
DOGWOOD THERAPEUTICS INC (DWTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-13.36).
The outstanding short interest for DOGWOOD THERAPEUTICS INC (DWTX) is 2.59% of its float. Check the ownership tab for more information on the DWTX short interest.
ChartMill assigns a technical rating of 1 / 10 to DWTX.
ChartMill assigns a fundamental rating of 3 / 10 to DWTX. While DWTX has a great health rating, there are worries on its profitability.
Over the last trailing twelve months DWTX reported a non-GAAP Earnings per Share(EPS) of -13.36. The EPS decreased by -97.93% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -24.3% | ||
ROE | -28.4% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to DWTX. The Buy consensus is the average rating of analysts ratings from 8 analysts.